Titre :

How to Choose the Optimal Starting Dose of Clomiphene Citrate (50 or 100 mg per Day) for a First Cycle of Ovulation Induction in Anovulatory PCOS Women?

Auteur(s) :

Huyghe, Lucie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Robin, Camille [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Dumont, Agathe [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Decanter, Christine [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Kyheng, Maéva [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Dewailly, Didier [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Jonard-Catteau, Sophie [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Robin, Geoffrey [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]

Titre de la revue :

Journal of Clinical Medicine

Nom court de la revue :

J Clin Med

Numéro :

12

Date de publication :

2023-08-12

ISSN :

2077-0383

Mot(s)-clé(s) en anglais :

polycystic ovary syndrome
clomiphene citrate
ovulation induction
antimullerian hormone
sex hormone binding globulin

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Research question: Clomiphene citrate (CC) is one of the first-line treatments for ovulation induction in women with anovulatory polycystic ovary syndrome (PCOS). However, nearly 1 out of 2 women is resistant to 50 mg/day ...
Lire la suite >Research question: Clomiphene citrate (CC) is one of the first-line treatments for ovulation induction in women with anovulatory polycystic ovary syndrome (PCOS). However, nearly 1 out of 2 women is resistant to 50 mg/day of CC. The objective of this study is to investigate the clinical, biological, and/or ultrasound factors that may predict the resistance to 50 mg/day of CC in the first cycle of treatment in women with anovulatory PCOS. This would make it possible to identify PCOS patients to whom the dose of 100 mg/day would be offered as of the first cycle. Design: A retrospective and monocentric study was conducted on 283 women with anovulatory PCOS who required the use of ovulation induction with CC (903 cycles). Results: During the first cycle of treatment, 104 patients (36.8%) were resistant to 50 mg/day of CC. Univariate regression analysis showed that patients who resisted 50 mg/day of CC had significantly higher BMI, waist circumference, serum levels of AMH, total testosterone, Δ4-androstenedione, 17-OHP, and insulin (p < 0.05), compared to patients ovulating with this dose. Serum levels of SHBG were significantly lower in patients resistant to 50 mg/day (p < 0.05). After multivariate analysis, only AMH and SHBG remained statistically significant (p = 0.01 and p = 0.001, respectively). However, areas under the ROC curves were weak (0.59 and 0.68, respectively). Conclusion: AMH and SHBG are the only two parameters significantly associated with the risk of resistance to 50 mg/day of CC. However, no satisfactory thresholds have been established to predict resistance to 50 mg CC.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172
• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2024-05-15T21:51:35Z
2024-05-31T08:53:05Z